Safety and efficacy claims made by US businesses marketing purported stem cell treatments and exosome therapies

Uncovering the gray zone: mapping the global landscape of direct-to-consumer businesses offering interventions based on secretomes, extracellular vesicles, and exosomes

(2023) Atiyeh Asadpour et al.   Stem Cell Research & Therapy

Online marketing practices of regenerative medicine clinics in US-Mexico border region: a web surveillance study

(2021) Javier Chavez et al.   Stem Cell Research & Therapy

Unproven stem cell interventions: A global public health problem requiring global deliberation

(2021) Zubin Master et al.   Stem Cell Reports

The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions

(2021) Leigh Turner   Cell Stem Cell

Online seminars as an information source for direct-to-consumer stem cell therapy

(2021) Mirna Hassoun et al.   Regenerative Medicine

Cell-based therapies for retinal diseases: a review of clinical trials and direct to consumer “cell therapy” clinics

(2021) John W. Hinkle et al.   Stem Cell Research & Therapy

Weighing up the evidence used by direct-to-consumer stem cell businesses

(2021) Margaret Cook et al.   Stem Cell Reports

Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood–Derived Products Marketed as Stem Cell Therapies

(2021) Kathleen P. Hartnett et al.   JAMA Network Open

The biology, function, and biomedical applications of exosomes

(2020) Raghu Kalluri et al.   SCIENCE

Clear Evidence of Safety and Efficacy Is Needed for Stromal Vascular Fraction Products: Commentary on “Arguments for a Different Regulatory Categorization and Framework for Stromal Vascular Fraction”

(2020) Peter W. Marks   STEM CELLS AND DEVELOPMENT

Rogue stem cell clinics

(2020) Iain R. Murray et al.   Bone & Joint Journal

Governmental Regulations and Increasing FDA Oversight of Regenerative Medicine Products: What's New in 2020?

(2020) William Fang et al.   ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY

Identifying the Risks of Unproven Regenerative Medicine Therapies

(2020) Peter W. Marks et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Assessing “cell therapy” clinics offering treatments of ocular conditions using direct-to-consumer marketing websites in the United States

(2019) Rajinder S. Nirwan et al.   OPHTHALMOLOGY

Characteristics and Scope of Training of Clinicians Participating in the US Direct-to-Consumer Marketplace for Unproven Stem Cell Interventions

(2019) Wayne Fu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

How to Peddle Hope: An Analysis of YouTube Patient Testimonials of Unproven Stem Cell Treatments

(2019) Bethany Hawke et al.   Stem Cell Reports

Characterizing Direct-to-Consumer Stem Cell Businesses in the Southwest United States

(2019) Emma K. Frow et al.   Stem Cell Reports

Direct-to-Consumer Advertising of Stem Cell Clinics

(2019) Christian A. Pean et al.   JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME

Online Direct-to-Consumer Advertising of Stem Cell Therapy for Musculoskeletal Injury and Disease

(2019) Matthew T. Kingery et al.   JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME

Too Much Carrot and Not Enough Stick in New Stem Cell Oversight Trends

(2018) Paul S. Knoepfler   Cell Stem Cell

Selling stem cells with tokens of legitimacy: An analysis of websites in Japan and Australia

(2018) T. Lysaght et al.   CYTOTHERAPY

Balancing Safety and Innovation for Cell-Based Regenerative Medicine

(2018) Peter Marks et al.   NEW ENGLAND JOURNAL OF MEDICINE

The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis

(2018) Paul S Knoepfler et al.   Regenerative Medicine

Selling stem cell ‘treatments’ as research: prospective customer perspectives from crowdfunding campaigns

(2018) Jeremy Snyder et al.   Regenerative Medicine

Direct-to-consumer marketing of stem cell interventions by Canadian businesses

(2018) Leigh Turner   Regenerative Medicine

The deadly business of an unregulated global stem cell industry

(2017) Tamra Lysaght et al.   JOURNAL OF MEDICAL ETHICS

Clarifying Stem-Cell Therapy’s Benefits and Risks

(2017) Peter W. Marks et al.   NEW ENGLAND JOURNAL OF MEDICINE

‘No one here's helping me, what do you do?’: addressing patient need for support and advice about stem cell treatments

(2017) Claire Tanner et al.   Regenerative Medicine

Open for business: a comparative study of websites selling autologous stem cells in Australia and Japan

(2017) Megan Munsie et al.   Regenerative Medicine

Marketing of unproven stem cell–based interventions: A call to action

(2017) Douglas Sipp et al.   Science Translational Medicine

Global Distribution of Businesses Marketing Stem Cell-Based Interventions

(2016) Israel Berger et al.   Cell Stem Cell

Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

(2016) Leigh Turner et al.   Cell Stem Cell

The Stem Cell Hard Sell: Report from a Clinic's Patient Recruitment Seminar

(2016) Paul S. Knoepfler   Stem Cells Translational Medicine

Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia

(2015) Alison K McLean et al.   Stem Cell Research & Therapy

Representations of Stem Cell Clinics on Twitter

(2014) Kalina Kamenova et al.   Stem Cell Reviews and Reports

U.S. Regulation of Stem Cells as Medical Products

(2012) D. Sipp et al.   SCIENCE

FDA Regulation of Stem Cell-Based Products

(2009) D. W. Fink   SCIENCE